CANNORDIC A/S is a Danish-based MedTech company committed to improving people's lives with products that make a difference. We combine science, nature, and passion to deliver innovative alternatives with high efficacy and bioavailability to patients, especially with autoimmune diseases. We research, develop, manufacture, commercialize and brand over-the-counter (OTC) products under pharmaceutical legislation. Currently, 21 products with cannabidiol aimed at autoimmune and stress-related diseases have been developed. The first 2 products reached Danish stores in 2020, and now 9 products are available on the European market at more than 500 points of sale. Another 12 products will be launched before the end of 2024, with 11 patent-pending products. The product line surpasses competing products on the market by being located at the intersection of natural products, science, and cannabinoid technology while certified under pharmaceutical legislation. To learn more about CANNORDIC and the Cannasen® brand, please visit cannordic.com and cannasen.dk